Atopic dermatitis and skin diseaseEmollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
Key words
Cited by (0)
This report presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (RP-PG-0407-10177). The views expressed in this report are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. United States–based contributions were made possible with funding from a Mentored Patient-oriented Research Career Development Award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (5K23AR057486). Support was also obtained from the Oregon Clinical and Translational Research Institute (OCTRI) and grant number 5 KL2 RR024141-04 from the National Center for Research Resources (NCRR; 5 KL2 RR024141-04), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Research in the McLean laboratory is funded by the Wellcome Trust (Programme Grant 092530/Z/10/Z and Strategic Award 098439/Z/12/Z). S.J.B. holds a Wellcome Trust Intermediate Clinical Fellowship WT086398MA.
Disclosure of potential conflict of interest: This study was funded by the National Institute for Health Research (RPPG-0407-10177). M. J. Cork has received compensation from Almirall Pharmaceuticals for membership on their advisory board; has received or has grants pending from Almirall Pharmaceuticals; and has received payment for delivering lectures, as well as compensation for travel and other meeting-related expenses, from Almirall, Astellas Pharma, and Steifel (a GlaxoSmithKline company). W. H. I. McLean's institution has received funding from the Wellcome Trust (WT086398MA), as has that of S. J. Brown, who also received an honorarium for speaking at the AAAAI annual meeting in 2012 and 2013. The rest of the authors declare that they have no relevant conflicts of interest.